Efficacy and safety of immune checkpoint inhibitors plus recombinant human endostatin therapy as second-line treatment in advanced non-small-cell lung cancer with negative driver gene: a pilot study

BACKGROUND: Immune checkpoint inhibitors (ICIs) have become the standard second-line treatment for advanced non-small cell lung cancer (NSCLC). Recent findings indicating an intertwined regulation of vascular endothelial growth factor (VEGF) signaling and immunosuppression in the tumor microenvironm...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Bo, Li, Yuzhi, Deng, Jie, Yang, Hui, Sun, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661927/
https://www.ncbi.nlm.nih.gov/pubmed/38023216
http://dx.doi.org/10.3389/fonc.2023.1210267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661927/
https://www.ncbi.nlm.nih.gov/pubmed/38023216
http://dx.doi.org/10.3389/fonc.2023.1210267

Ejemplares similares